192 Photos and videos
🤝Thanks for all your input!
👌Now let’s get your ?s answered
#MondayNightIBD ~ #IL23 & #IL23p19 in #IBD 🎥
w/⭐️@BattatMD4IBD & @DCharabaty
Supported by an edu grant from @EliLillyandCo
🖱️Click👇to watch
🗳️Answer 🎥#IBDPolls
🏆Claim🆓#CME from @Global_CME using🔗👇
x.com/i/broadcasts/1pKdRbRRO…
1
3
7
233
2/#CME➡️mnibd.short.gy/IL23sVideo3po…
🔴Post #IBDPoll 1️⃣
42yo new dx of UC pancolitis, was started on miri, now in remission @ 1yr
He's anxious about his chances of remaining in remission over time
In #LUCENT RCT, what % of pts in remission at Wk52 remained in remission @ yr 2&3?
0%
<50%
0%
~60%
0%
~70%
0%
>80%
0 votes • Final results
1
32
3/#MondayNightIBD
#CME🏅➡️mnibd.short.gy/IL23sVideo3po…
🔴Post #IBDPoll 2️⃣
In a patient with #Crohns ileocolitis who lost response to IFX (therapeutic drug level, no antibodies),
What 2nd line biologic would have the highest efficacy?
0%
Adalimumab
0%
Ustekinumab
0%
An IL23p19
0%
Vedolizumab
0 votes • Final results
33
#NDMM Quad Tx Efficacy 🎥 Discussion w/ @DrKrinaPatel & @JMikhaelMD #MMSM x.com/i/broadcasts/1lPKqvyQw…
1
36
2/🥼Tune in to learn about efficacy of quad tx in #NDMM w⭐️ @DrKrinaPatel & @JMIkhaelMD
🚦3 quick steps &🆓 #CME
🔴Watch🎥⬆️
🟡Answer post-poll
🟢🏆Claim CME from @BonumCE👉bonumce.short.gy/NDMMVideoPo…
Supported by an edu grant from @JNJInnovMed
1
33
3/ #OncTwitter #mmsm
🫥Didn’t answer the pre-polls yet?
⏱️Do so now before moving on👉🔗
🔰bonumce.short.gy/NDMMVideoPr…
🟠Next, let us know; what’s your specialty?
0%
Hem Onc
0%
Med, Surg, Rad Onc
0%
Other MD/DO or APP
0%
PharmD, RN, Other HCP
0 votes • Final results
35
Bonum CE retweeted
23 Sep 2025
#MMSM #OncTwitter #oncX
⚡️Join me & my colleague @jmikhaelmd
🧵Explore efficacy of quad tx in #NDMM
🔬PERSEUS, GMMG-HD7 & CONCEPT, CEPHEUS, IMROZ, ADVANCE, MIDAS
🆓#CME 👉🏼 bonumce.short.gy/NDMM-TW1-CM…
Supported by an edu grant from @JNJInnovMed
📍First, what's your specialty?
94%
Hem/Onc
6%
Med Onc
0%
Rad, SurgOnc, Other MD/DO
0%
APP, RN, PharmD, OtherHCP
17 votes • Final results
1
7
14
2,643
Bonum CE retweeted
23 Sep 2025
2/ Before we jump in, a few disclosures & important links🔗
1️⃣📖#CME info bonumce.short.gy/NDMM-TW1-CM…
2️⃣Take the pre-survey👉bonumce.short.gy/NDMM-TW1-Pr…
3️⃣Get the latest NDMM quad tx efficacy data w/ 🧵👇
4️⃣🏆Claim🆓CME bonumce.short.gy/NDMM-TW1-Po…
Now, let's get started!
1
2
5
308
Bonum CE retweeted
23 Sep 2025
3/ 🥼In your practice, which regimen are you using most often for 1L therapy in pts w/ transplant eligible(TE) #NDMM?
☎️Phoning friends…What do you do? @RahulBanerjeeMD @PlasmaCellPete @SagarLonialMD @DoctorAKrishnan @NoopurRajeMD @End_myeloma @TomBmt133 @HiraSMian @Mohty_EBMT
62%
DVRd quad
0%
IsaVRd quad
31%
DKRd or IsaKRd quad
6%
VRd or other triplet
16 votes • Final results
1
1
4
248
Bonum CE retweeted
23 Sep 2025
4/💃Quads are taking center stage in #NDMM
Let’s look @ the📈on quad tx
PERSEUS ~🔑trial: SQ dara➕VRd➡️↑outcomes in TE pts
👉↑PFS @ 48m 84.3 v 67.7%; HR: 0.42; P<0.001
👉↑MRD- rate 75.2 v 47.5%; P<0.001
👉↑CR rate 87.9 v 70.1%; P<0.001
🎉🆕SOC ~ quad instead of triplet🎉
1
2
7
330
Bonum CE retweeted
23 Sep 2025
5/PERSEUS #ASCO25: sustMRD- in pts on quad maint @ median f/u 47.5m
↑ ustMRD- @ ≥24m w DVRd v VRd: 55.8 v 22.6%
👉Pts w ≥12m sustMRD-: ↑ 48m PFS,regardless of tx
👉Only 3.1% progressn @18m w DVRd v 6.8% VRd
🔑DVRd➡️2.5x⬆️≥24m sustMRD- & ½ progressn risk @≤18m tx
@mbeksac56
1
2
7
310
Bonum CE retweeted
23 Sep 2025
6/🙋🏻What about replacing dara- with isa- in a quad?
GMMG-HD7: IsaVRd v VRd induction➡️isa-len v len maintenance in TE NDMM
👉↑ MRD- rate 50% v 36%; p =0.00017
👉IsaVRd had ↓AE rates & ↓d/c rates v RVd
🎉🆕SOC
👉Results➡️addition of IsaVRd as induction regimen for TE #NDMM
1
4
8
539
Bonum CE retweeted
23 Sep 2025
7/⚡️GMMG-HD7 #ASCO25 update w/ PFS benefit in all quad recipients
↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD (HR 0.61; P=0.002)
🔮Maint w Isa-len v len is on-going
1
1
7
253
Bonum CE retweeted
23 Sep 2025
8/🔬Exciting news for #mmsm
Quad tx as🆕SOC for #NDMM
Current @EHA_Hematology/@EMN_EuMMnet (1st optn) & @NCCN (pref,cat 1) regimens for TE pts w/NDMM:
🎯DaraVRd➡️SCT➡️len maint
🎯IsaVRd SCT➡️len maint
👏to quad as 1L for TE pts👏
…but what about pts who are TIE /SCT-deferred?
1
1
6
230
Bonum CE retweeted
23 Sep 2025
9/CEPHEUS compared induction/consolidation w VRd ± daratumumab (D) followed by maintenance in transplant-ineligible (TIE) NDMM
🗳️The DVRd arm demonstrated which of the following outcomes?
@AlGarfall @bdermanmd @mvmateos @OcioEnrique
#OncTwitter #OncX #Oncology #MedTwitter
89%
Deep, more durable MRD-
11%
⬆️MRD- rates. No🔺in PFS
0%
Similar efficacy, ⬆️VTE
0%
⬆️ D/C rate in DVRd arm
9 votes • Final results
1
1
5
258
Bonum CE retweeted
23 Sep 2025
10/ CEPHEUS🔑trial in TIE & SCT-deferrd pts
DVRd➡️deeper, more durable MRD- rate
TIE cohort:
👉Overall MRD- 63.2 v 41.4%
👉SustMRD @ ≥12m 48.7 v 26.3%; P<0.0001
👉CR 81.2 v 61.6%; P<0.0001
👉HR 0.57, 95% CI 0.41-0.79; P=0.0005
↓D/C rate w quad
🎉DVRd new SOC for TIE NDMM🎉
1
1
9
2,932
Bonum CE retweeted
23 Sep 2025
11/Do results w isa show similar trends?
IMROZ🔑trial
IsaVRd➡️IsaRd v VRd➡️Rd in TIE pts w NDMM
👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
↑ CR: 74.7% v 64.1%; P=0.01
🎉IMROZ results support IsaVRd as 🆕SOC for TIE #NDMM pts
@szusmani
1
1
7
254
Bonum CE retweeted
23 Sep 2025
12/BENEFIT eval'd wkly bortezomib (V) in TIE NDMM
IsaVRd➡️IsaVR➡️IsaR v IsaRd➡️IsaR➡️IsaR
↑MRD- rate @
12mo 51% v 21%; OR: 3.88; 95%CI: 2.27-6.62;P<0.0001
18mo 53% v 26%; OR: 3.16; 95%CI: 1.89-5.28;P<0.0001
🔑Wkly V in IsaRd=deep responses
Supports IsaVRd as🆕SOC for TIE NDMM
1
1
5
216
Bonum CE retweeted
23 Sep 2025
13/🆕SOC for pts w SCT-deferred or TIE #NDMM🎉
NCCN (preferred, cat 1) & EHA-EMN (1st optn) regimens:
🎯DRd ‘til progression; de-escalate prn
🎯DVRd ‘til progression; de-escalate prn (<80 yr old, not frail)
🎯IsaVRd ‘til progression; de-escalate prn (<80 yr old, not frail)
#MMSM
1
2
6
524
Bonum CE retweeted
23 Sep 2025
14/Unfortunately, pts w high-risk (HR) #NDMM have 👎poorer prognosis & shorter survival rates vs standard-risk
Based on results of GMMG-CONCEPT presented at #ASCO2025, which treatment strategy should be used for pts w/ HR NDMM?
Key:
🔸MRD- = Treat to MRD-
#MMSM #OncTwitter
9%
Initiate allogeneic SCT
9%
Choose IV instead of subQ
9%
🔸MRD- then d/c tx
73%
🔸MRD- & cont maintenance
11 votes • Final results
1
1
4
228